R325
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 62
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.530
- ANDROGEN_RESPONSE+0.380
- TGF_BETA_SIGNALING+0.370
- UV_RESPONSE_DN+0.360
- MTORC1_SIGNALING+0.330
- BILE_ACID_METABOLISM+0.260
- ADIPOGENESIS+0.250
- MYC_TARGETS_V1+0.250
- CHOLESTEROL_HOMEOSTASIS+0.230
- KRAS_SIGNALING_UP+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- INTERFERON_GAMMA_RESPONSE-0.360
- WNT_BETA_CATENIN_SIGNALING-0.310
- MYC_TARGETS_V2-0.290
- HEDGEHOG_SIGNALING-0.250
- ALLOGRAFT_REJECTION-0.190
- KRAS_SIGNALING_DN-0.190
- IL6_JAK_STAT3_SIGNALING-0.160
- TNFA_SIGNALING_VIA_NFKB-0.120
- COMPLEMENT-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A0AD-01A-11R-A056-07 | — | B | 0.802 |
| 2 | MBCProject_5953_T1_RNA | — | B | 0.796 |
| 3 | TCGA-BH-A1FM-01A-11R-A13Q-07 | — | B | 0.784 |
| 4 | TCGA-D8-A1X7-01A-11R-A14M-07 | — | B | 0.759 |
| 5 | TCGA-BH-A1F2-01A-31R-A13Q-07 | — | B | 0.737 |
| 6 | TCGA-AC-A23H-01A-11R-A157-07 | — | C | 0.716 |
| 7 | DRR168580 | — | — | 0.716 |
| 8 | TCGA-A1-A0SJ-01A-11R-A084-07 | — | B | 0.714 |
| 9 | MBCProject_1046_T1_RNA | — | C | 0.713 |
| 10 | TCGA-A2-A0ER-01A-21R-A034-07 | — | B | 0.704 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.530 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |